Protection of mice against fission neutron irradiation by WR-2721 or WR-151327.
Two phosphorothioate compounds, WR-2721 and WR-151327, were examined for their radioprotective efficacies against the effects of fission neutron irradiation in male and female mice. Within sex groups no significant difference in lethality at 30 or 100 days postirradiation was found between WR-2721 or WR-151327 pretreatment. The dose modification factors (DMFs) for male mice treated with either compound were 1.29 (LD50/30) and 1.24 (LD50/100), and those for drug-treated female mice were 1.21 (LD50/30) and 1.19 (LD50/100). Both WR-2721 and WR-151327 were found to be equally radioprotective when compared using DMFs as the end point. WR-151327 (500 mg/kg, ip) was found to be significantly more toxic to both male and female B6D2F1 mice than equimolar amounts of WR-2721. Small but significant sex differences in radioprotection were found: the DMFs for female mice pretreated with either compound were lower than those for similarly treated male mice; the incidence of mortality 31-100 days postexposure in male mice pretreated with WR-151327 was greater than for female mice. In addition, sex differences were noted in drug toxicity. Toxic death in female mice given WR-151327 (500 mg/kg, ip) is 2.6 times more probable than in males.
D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D005260:Female; D008297:Male; D051379:Mice; D009502:Neutrons; D009946:Organothiophosphorus Compounds / Q000494:pharmacology*; D011829:Radiation Dosage; D011837:Radiation-Protective Agents; D012737:Sex Factors; D013997:Time Factors; D014916:Whole-Body Irradiation
D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; C048392:WR 151327; D004999:Amifostine